Adoptive T-cell therapy with genetically modified chimeric antigen receptor (CAR) targeting CD19 (CART19) has shown great potential for treatment of B-cell malignancies.[1–3] For patients with relapsed/refractory B-cell NHL, an overall response rate is about 70% to 80% and the complete remission (CR) rate is about 40% to 50% after CART19 treatment.[4] Thus, the efficacy of chimeric antigen receptor T cell (CAR-T) strategy for B-cell NHL still needs substantial improvement. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.